Patents Examined by Vasu S. Jagannathan
  • Patent number: 5686288
    Abstract: A novel gene, huntingtin, is described, encoding huntingtin protein, recombinant vectors and hosts capable of expressing huntingtin. Methods for the diagnosis and treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: November 11, 1997
    Assignee: The General Hospital Corporation
    Inventors: Marcy E. MacDonald, Christine M. Ambrose, Mabel P. Duyao, James F. Gusella
  • Patent number: 5686521
    Abstract: A milled carbon fiber reinforced polymer having increased abrasion resistive characteristics. The reinforced polymer comprises a base resin selected from the group consisting of polyolefins and polyamides. The base resin is combined with an amount of milled carbon fibers and further may be combined with polytetrafluoroethylene. The resulting composite materials have excellent friction and wear characteristics and are useful in the production of injection molded parts. The molded parts have a high impact strength, exhibit dimensional stability, are abrasion resistive, and are static dissipative, with the composite materials having particular utility as support fixtures for semiconductors during certain processing operations.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: November 11, 1997
    Assignee: Empak, Inc.
    Inventors: Brian Massengale, Paul Schauer, Charles Dahle, Barry Gregerson, Bonnie Bachman, Thomas Oesterle
  • Patent number: 5683898
    Abstract: There is provided an advantageous process for production of EPA by a gene recombinant technique wherein genes coding for biosynthesis enzymes for eicosapentaenoic acid (EPA) useful as pharmaceuticals, agrochemicals, foods, feeds or the like is obtained from microorganisms.EPA is produced by obtaining genes coding for eicosapentaenoic acid (EPA) biosynthesis enzymes, constructing a plasmid by joining the genes to a vector, transforming E. coli with the plasmid, and culturing the transformed E. coli.
    Type: Grant
    Filed: January 20, 1995
    Date of Patent: November 4, 1997
    Assignee: Sagami Chemical Research Center
    Inventors: Kazunaga Yazawa, Akiko Yamada, Seishi Kato, Kiyosi Kondo
  • Patent number: 5683894
    Abstract: A method for producing pure, active, mature recombinant Nerve Growth Factor-beta is disclosed, as is the protein so produced.
    Type: Grant
    Filed: March 7, 1991
    Date of Patent: November 4, 1997
    Assignee: University of California
    Inventors: Robert H. Edwards, William J. Rutter
  • Patent number: 5681725
    Abstract: Process for producing an extracellular heme protein in increased yields, the process comprising culturing an apoprotein producing microorganism in a fermentation medium containing heme or a heme-containing material under conditions permitting the production of active, recombined heme protein, and recovering the resulting heme protein from the culture medium.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: October 28, 1997
    Assignee: Novo Nordisk A/S
    Inventor: Ejner Bech Jensen
  • Patent number: 5681720
    Abstract: Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least one amino acid by a different amino acid and/or deletion of at least one amino acid, recombinant plasmids containing a DNA fragment insert coding for any of these hG-CSF polypeptide derivatives, microorganisms carrying one of such plasmids, methods of producing the hG-CSF polypeptide derivatives using the microorganisms, a monoclonal antibody binding to the hG-CSF polypeptide derivative, and chemically modified hG-CSF or derivatives thereof are disclosed.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: October 28, 1997
    Assignee: Kyowa Hakko Co., Ltd.
    Inventors: Tetsuro Kuga, Hiromasa Miyaji, Moriyuki Sato, Masami Okabe, Makoto Morimoto, Seiga Itoh, Motoo Yamasaki, Yoshiharu Yokoo, Kazuo Yamaguchi, Hajime Yoshida, Yoshinori Komatsu
  • Patent number: 5679552
    Abstract: A desired protein having the formula:A--B--C--Pwhereina) A is Lys or Arg, and B and C are arbitrary amino acids, orb) A is an arbitrary amino acid different from Pro, Lys and Arg, and B and/or C is Pro,is produced from a biosynthetically formed amino acid extended protein having the formula:X--A--B--C--Pwherein A, B, C and P are as defined above, and X is an amino acid sequence with an even number of amino acids, of which the first one, seen from the N-terminal end, is different from Lys and Arg, all other uneven amino acids are different from Pro, Lys and Arg, and all even amino acids are different from Pro, by reaction with the enzyme dipeptidyl aminopeptidase (DAP I). The desired protein is obtained in a pure state. Thus, e.g. hGH without content of Met-hGH may be produced by the process.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: October 21, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Henrik Dalb.o slashed.ge, John Pedersen, Thorkild Christensen, J.o slashed.rli Winnie Ringsted, Torben Ehlern Jessen
  • Patent number: 5679550
    Abstract: The present invention provides a polypeptide represented by the following amino acid sequence: ##STR1## wherein n is 0 or 1 and X represents Pro Ala Gly Thr Arg Ala Asn Asn Thr Leu Leu Asp Ser Arg Gly Trp Gly Thr Leu Leu Ser Arg Ser Arg Ala Gly or a fragment thereof (n=0: SEQ ID NO:1, n=1: SEQ ID NO:2), a recombinant DNA coding for the polypeptide, a vector containing the recombinant DNA, the preparation of a transformant carrying the vector, and the production of the polypeptide with the transformant. The use of this peptide in pharmaceutical compositions is also provided.
    Type: Grant
    Filed: October 31, 1995
    Date of Patent: October 21, 1997
    Assignees: Takeda Chemical Industries, Inc., President of National Cancer Center
    Inventors: Koji Yoshimura, Kaori Ishimaru, Koichi Igarashi, Masaaki Terada
  • Patent number: 5679740
    Abstract: Mechanically stable, self-inverting water-in-oil polymer emulsions for use in industrial water treatment, waste water treatment, sludge conditioning, ore dressing, papermaking, secondary and tertiary oil recovery containing carboxylated ethoxylated phenols and alcohols are provided.
    Type: Grant
    Filed: June 13, 1996
    Date of Patent: October 21, 1997
    Assignee: Cytec Technology Corp.
    Inventor: Howard Ivan Heitner
  • Patent number: 5677274
    Abstract: The present invention provides a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the anthrax protective antigen (PA) binding domain of the native anthrax lethal factor (LF) protein and a nucleotide sequence encoding an activity inducing domain of a second protein. Also provided is a nucleic acid encoding a fusion protein comprising a nucleotide sequence encoding the translocation domain and LF binding domain of the native anthrax PA protein and a nucleotide sequence encoding a ligand domain which specifically binds a cellular target. Proteins encoded by the nucleic acid of the invention, vectors comprising the nucleic acids and hosts capable of expressing the protein encoded by the nucleic acids are also provided. A composition comprising the PA binding domain of the native LF protein chemically attached to a non-LF activity inducing moiety is further provided. A method for delivering an activity to a cell is provided.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: October 14, 1997
    Assignee: The Government of the United States as represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Kurt R. Klimpel, Naveen Arora, Yogendra Singh, Peter J. Nichols
  • Patent number: 5676941
    Abstract: Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor ("hpG-CSF") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: October 14, 1997
    Assignee: Amgen Inc.
    Inventor: Lawrence M. Souza
  • Patent number: 5676940
    Abstract: A method of reducing immunoglobulin E responses associated with certain immune disorders is provided. The method comprises administering an effective amount of an antagonist to human interleukin-4. Preferably, the antagonist is a blocking monoclonal antibody specific for human interleukin-4, or a fragment or binding composition derived therefrom.
    Type: Grant
    Filed: March 17, 1994
    Date of Patent: October 14, 1997
    Assignee: Schering Corporation
    Inventors: Robert L. Coffman, Jan Egbert de Vries
  • Patent number: 5677163
    Abstract: There are described, cleaning compositions comprising proteolytic enzymes having enhanced thermal and/or alkaline stability. Particularly, the compositions comprise a Bacillus sp. subtilisin having enhanced thermal stability and alkaline stability. The composition may be useful for any cleaning application such as laundry cleaning, household cleaning (dishcare, hard surface cleaning) or industrial cleaning.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: October 14, 1997
    Assignee: Genencor International, Inc.
    Inventors: Stanley E. Mainzer, Pushkaraj L. Lad, Brian F. Schmidt
  • Patent number: 5674708
    Abstract: The present invention provides an analogue of human .alpha.-1-antichymotrypsin wherein the amino acid at position 358 is selected from the group consisting of isoleucine, valine, alanine, aspattic acid, threonine, and glutamic acid.
    Type: Grant
    Filed: March 31, 1994
    Date of Patent: October 7, 1997
    Assignee: Trustees of the University of Pennsylvania
    Inventors: Barry S. Cooperman, Harvey Rubin, Norman Schechter, Zhi Mei Wang
  • Patent number: 5670618
    Abstract: A purified insulin-like protein (ILP) isolated from Saccharomyces cerevisiae is disclosed. The ILP has a molecular weight of approximately 6.4 kilodaltons and the amino acid sequence of the 22 amino terminal residues of the protein has been determined. Computer-assisted molecular graphics analysis of ILP illustrates the similarity of the sequenced portion to vertebrate insulin A-chains.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: September 23, 1997
    Assignee: The State University of New Jersey
    Inventor: Maureen A. McKenzie
  • Patent number: 5670616
    Abstract: Synthetic biopolymers can be prepared using recombinant DNA technology or chemical synthetic methods which have properties similar to naturally occuring gelatin or collagen. These materials comprise one or more polypeptides having the peptide sequence represented by the formulaeI:{?(Gly Pro Gln)(Gly Pro Glu).sub.4 !.sub.2 }.sub.nII:Gly Pro Glu{?(Gly Pro Gln)(Gly Pro Glu).sub.4 !.sub.2 }.sub.nIII:Gly Pro Xaa.sub.1 Gly Leu Xaa.sub.2 Gly Pro Arg Gly Pro Pro Gly Ala Set Gly Ala Pro Gly Pro Glu Gly Phe Gln GlywhereinXaa.sub.1 and Xaa.sub.2 are independently the amino acids identified as Met, Ile, His, Lys, Asn, Tyr or Gln, and n is 1 to 25.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: September 23, 1997
    Assignee: Eastman Kodak Company
    Inventors: Shane Crawford Weber, John Alan McElver
  • Patent number: 5670341
    Abstract: Methods and compositions are disclosed for producing human somatomedin carrier protein-like polypeptides. Human somatomedin carrier protein-like polypeptides, which bind somatomedins, are produced using recombinant technology. Also disclosed are methods for making complexes of human somatomedin carrier protein-like polypeptides and somatomedins.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: September 23, 1997
    Assignee: Celtrix Pharmaceuticals, Inc.
    Inventors: Emerald Martin Spencer, Carol Talkington-Verser
  • Patent number: 5670146
    Abstract: Highly purified Pluripotent hematopoietic colony-stimulating factor (pluripotent CSF), a glycoprotein (MW 19,600) constitutively produced by human tumor cells has been highly purified from low serum-containing conditioned medium to apparant homogeneity. Pluripotent CSF supports the growth of human mixed colonies (CFU-GEMM), granulocyte-macrophage colonies (CFU-GM), early erythroid colonies (BFU-E) and induces differentiation of human leukemic cells. The specific activity of the purified pluripotent CSF in the CFU-GM assay is 1.5.times.10.sup.8 U/mg protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 23, 1997
    Assignee: Sloan-Kettering Institute
    Inventors: Karl Welte, Erich Platzer, Janice L. Gabrilove, Roland Mertelsm, Malcolm A. S. Moore
  • Patent number: 5665563
    Abstract: A method for producing protein from DNA in a static reaction in which DNA, ribonucleotide triphosphates, magnesium and a RNA polymerase are mixed and incubated during which RNA is transcribed from the DNA and the resulting solution is added to a eukaryotic cell-free extract containing magnesium so that the RNA produced during the incubating step translates into protein and so that further transcription of the DNA is coupled to translation of the resulting RNA into protein.
    Type: Grant
    Filed: February 13, 1995
    Date of Patent: September 9, 1997
    Assignee: Promega Corporation
    Inventor: Gregory S. Beckler
  • Patent number: 5665564
    Abstract: Doxorubicin resistance can be conferred on a host by transforming the host with a recombinant vector comprising a DNA having the configuration of restriction sites shown in FIGS. 1 or 2 of the accompanying drawings or a restriction fragment derived therefrom containing a gene coding for doxorubicin resistance.
    Type: Grant
    Filed: August 9, 1993
    Date of Patent: September 9, 1997
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Marinella Caruso, Anna Luisa Colombo, Luisa Garofano, Francesca Torti, Guiseppe Zanella